SCHEMBL3600677

SCHEMBL3600677

O=C1C=C(c2cn(-c3ccccc3)c3ccccc23)C(=O)N1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
POLB P06746 2/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
GSK3B P49841 5/20 0.42
PRKCB P05771 3/20 0.42
PRKCA P17252 3/20 0.42
PRKCG P05129 2/20 0.42
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
NR4A2 P43354 1/20 0.40
CCNE2 O96020 1/20 0.39
CDK4 P11802 1/20 0.39
CCND1 P24385 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127976 0.87 GSK3B (0.56) KDM4EPOLBCTDSP1GSK3BPRKCB
SCHEMBL6344338 0.81 GSK3B (0.41) KDM4EPOLBCTDSP1GSK3BPRKCB
SCHEMBL4848432 0.80 CDK2 (0.39) POLBGSK3BPRKCBPRKCAPRKCG
SCHEMBL3785977 0.80 ALOX5 (0.40) GSK3BPRKCBPRKCAPRKCGPTPRC
SCHEMBL29504831 0.79 CCNE2 (0.63) GSK3BPRKCACCNE2CDK4CCND1
SCHEMBL5879232 0.79 CCNE2 (0.63) GSK3BPRKCACCNE2CDK4CCND1
SCHEMBL2954257 0.79 GSK3B (0.43) GSK3BPRKCBPRKCAPRKCGCCNE2
Hydrochloric Acid SCHEMBL29664072 0.78 CCNE2 (0.61) GSK3BPRKCACCNE2CDK4CCND1
SCHEMBL3774109 0.78 GSK3B (0.66) GSK3BPRKCBPRKCAPRKCGCCNE2
SCHEMBL6344642 0.77 PRKCB (0.49) GSK3BPRKCBPRKCAPRKCGPRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100240650-A1 SUBSTITUTED PYRROLINES AS KINASE INHIBITORS ZHANG HAN-CHENG 2010-09-23 US disclosed
US-7608634-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2009-10-27 US disclosed
US-20070213387-A1 Substituted pyrrolines as kinase inhibitors ZHANG HAN-CHENG 2007-09-13 US disclosed
US-7232906-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BG) 2007-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240650-A1 SUBSTITUTED PYRROLINES AS KINASE INHIBITORS PRKDC, MAP2K2, TTK KDM4E 1292/4885POLB 1342/4885CTDSP1 568/4885
US-20070213387-A1 Substituted pyrrolines as kinase inhibitors PRKDC, MAP2K2, TTK KDM4E 1292/4885POLB 1342/4885CTDSP1 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.